BrazilAIM to showcase life sciences supply chain expertise at LogiPharma 2025
Taking place next month, LogiPharma will see leaders from around the world travel to France to gain insight in the latest trends and developments in the world of life sciences supply chain. As one of the event’s partners, AIM will play an important role in sharing knowledge and shaping discussions.
Now in its 25th year, LogiPharma is the world’s largest event for supply chain leaders in the life sciences sector, with over 2,500 participants set to visit Lyon between April 8 to 10 to attend the congress.
The agenda will see supply chain leaders from companies such as Pfizer, Sanofi, Moderna, Novartis, Gilead, Johnson & Johnson, Bristol Myers Squibb, AstraZeneca, and Novo Nordisk take the stage to outline trends that are reshaping the sector in 2025, including supply chain redesign and reshoring, geopolitical risks, product complexity and its impact on logistics, emerging technologies, artificial intelligence, net zero and much more.
Over the course of the 3-day event, attendees will be provided with an action-packed agenda consisting of keynotes, plenary sessions, special functional tracks, masterclasses and panel discussions, with the event’s exhibition area facilitating information exchanges and networking opportunities between companies and service providers active in the pharmaceutical industry.
Knowledge Partner: AIM
Among the line-up of thought leaders and exhibitors is AIM, an award-winning supply chain consultancy dedicated to the life science industry. The firm, which is a subsidiary of US-headquartered group Blue Matter, specializes in supporting life science, biotech and pharma companies with designing, building and sustaining efficient supply chains and supply chain operations.
AIM’s participation this year includes a thought leadership session where the firm will share lessons learned from supporting entry into the Gulf region. In 2024, Agios Pharmaceuticals began preparing to enter the GCC region through a distribution agreement with a local player. AIM was a key partner in advising on regulatory, partnering and supply chain approaches for this project.
Led by Wendy Xia, Vice President Supply Chain at Agios Pharmaceuticals, and Ronald van Zitteren, Principal at AIM, the session will inform participants about key factors to consider when launching in the GCC, the importance of cross-functional collaboration and the pivotal role supply chain plays in such expansion projects.
Additionally, AIM Principal Peter Martens will be involved in a panel discussion titled ‘How can you develop collaborative roadmaps to deliver better clinical-to-commercial scale up and launch management activities.’ The panel will discuss challenges companies may face when transitioning from clinical trials to a commercial launch, exploring the key role supply chain should play in this process and capabilities.
Meanwhile, AIM will for the third year in a row have its own booth, where the consultancy firm will showcase its expertise and offerings to clients and partners in the value chain.